Franz H Messerli

List of Publications by Year
in descending order

227 papers	22,382 citations	18482 62 h-index	8630 146 g-index
234 all docs	234 docs citations	234 times ranked	22103 citing authors

#	Article	IF	Citations
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	A Calcium Antagonist vs a Nonâ€"Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	7.4	1,107
3	Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. American Journal of Medicine, 2007, 120, 713-719.	1.5	900
4	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. American Journal of Medicine, 2003, 115, 41-46.	1.5	686
5	Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?. Annals of Internal Medicine, 2006, 144, 884.	3.9	664
6	Essential hypertension. Lancet, The, 2007, 370, 591-603.	13.7	574
7	Are Î²-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?. JAMA - Journal of the American Medical Association, 1998, 279, 1903.	7.4	488
8	Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose. Circulation, 2011, 123, 2799-2810.	1.6	397
9	Î²-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	7.4	377
10	Serum Uric Acid in Essential Hypertension: An Indicator of Renal Vascular Involvement. Annals of Internal Medicine, 1980, 93, 817.	3.9	375
11	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€^168 participants from randomised trials. Lancet Oncology, The, 2011, 12, 65-82.	10.7	332
12	J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal, 2010, 31, 2897-2908.	2.2	318
13	The Transition From Hypertension toÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 543-551.	4.1	305
14	Secondary arterial hypertension: when, who, and how to screen?. European Heart Journal, 2014, 35, 1245-1254.	2.2	258
15	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 376, 1332-1340.	27.0	229
16	Clinical Outcomes with Î²-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. American Journal of Medicine, 2014, 127, 939-953.	1.5	224
17	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Progress in Cardiovascular Diseases, 2020, 63, 682-689.	3.1	221
18	Vasopeptidase inhibition and angio-oedema. Lancet, The, 2000, 356, 608-609.	13.7	215

#	Article	IF	Citations
19	Angiotensin-Converting Enzyme Inhibitors in Hypertension. Journal of the American College of Cardiology, 2018, 71, 1474-1482.	2.8	215
20	Cardiovascular Protection Using Beta-Blockers. Journal of the American College of Cardiology, 2007, 50, 563-572.	2.8	214
21	Osler's Maneuver and Pseudohypertension. New England Journal of Medicine, 1985, 312, 1548-1551.	27.0	213
22	The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension. Journal of the American College of Cardiology, 2009, 54, 1827-1834.	2.8	213
23	Coronavirus Disease 2019 (COVIDâ€19): Do Angiotensinâ€Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?. Journal of the American Heart Association, 2020, 9, e016509.	3.7	210
24	Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension. American Journal of Medicine, 2012, 125, 14-22.	1.5	204
25	Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiology, 2020, 5, 745.	6.1	197
26	Relation of Beta-Blockerâ€“Induced Heart Rate Lowering and Cardioprotection in Hypertension. Journal of the American College of Cardiology, 2008, 52, 1482-1489.	2.8	191
27	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ, The, 2013, 346, f360-f360.	6.0	185
28	Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. Hypertension, 2007, 50, 299-305.	2.7	174
29	Chocolate Consumption, Cognitive Function, and Nobel Laureates. New England Journal of Medicine, 2012, 367, 1562-1564.	27.0	158
30	Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. Journal of the American College of Cardiology, 2015, 65, 1539-1548.	2.8	156
31	Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. Journal of the American College of Cardiology, 2011, 57, 590-600.	2.8	148
32	Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Reninâ€“Angiotensin System Inhibitors. American Journal of Cardiology, 2012, 110, 383-391.	1.6	145
33	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. American Journal of Medicine, 2017, 130, 707-719.e8.	1.5	142
34	Disparate Cardiovascular Findings in Men and Women with Essential Hypertension. Annals of Internal Medicine, 1987, 107, 158.	3.9	141
35	Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome. European Heart Journal, 2011, 32, 2231-2235.	2.2	141
36	Effect of Allopurinol on Blood Pressure: A Systematic Review and Metaâ€Analysis. Journal of Clinical Hypertension, 2013, 15, 435-442.	2.0	141

#	Article	IF	Citations
37	Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy. American Journal of Medicine, 2010, 123, 719-726.	1.5	139
38	Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ, The, 2016, 352, i438.	6.0	135
39	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	2.8	124
40	Association of Assisted Reproductive Technologies With Arterial Hypertension During Adolescence. Journal of the American College of Cardiology, 2018, 72, 1267-1274.	2.8	123
41	Cerebroprotection mediated by angiotensin II. Journal of the American College of Cardiology, 2004, 43, 1343-1347.	2.8	122
42	Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ: British Medical Journal, 2011, 342, d2234-d2234.	2.3	121
43	Risk/Benefit Assessment of Î²-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. Circulation, 2008, 117, 2706-2715.	1.6	117
44	Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. Journal of the American College of Cardiology, 2017, 69, 486-493.	2.8	117
45	Vasodilatory edema: A common side effect of antihypertensive therapy. Current Cardiology Reports, 2002, 4, 479-482.	2.9	116
46	Beyond salt: lifestyle modifications and blood pressure. European Heart Journal, 2011, 32, 3081-3087.	2.2	111
47	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373.	2.2	103
48	Body Weight Changes with Î²-Blocker Use: Results from GEMINI. American Journal of Medicine, 2007, 120, 610-615.	1.5	95
49	Angiotensin II Receptor Inhibition. Archives of Internal Medicine, 1996, 156, 1957.	3.8	91
50	Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension. Journal of the American College of Cardiology, 2008, 52, 1062-1072.	2.8	90
51	Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference. American Journal of Medicine, 2010, 123, 1016-1030.	1.5	90
52	Hypertension management 2011: optimal combination therapy. European Heart Journal, 2011, 32, 2499-2506.	2.2	87
53	Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. European Heart Journal, 2015, 36, 1967-1973.	2.2	87
54	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clinic Proceedings, 2016, 91, 51-60.	3.0	86

#	Article	IF	Citations
55	Isolated Systolic Hypertension: An Update After SPRINT. American Journal of Medicine, 2016, 129, 1251-1258.	1.5	85
56	The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. European Heart Journal, 2010, 31, 552-560.	2.2	79
57	Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease. American Journal of Medicine, 2014, 127, 71-81.e1.	1.5	77
58	Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-hÂAmbulatory Blood Pressure Monitoring. Journal of the American College of Cardiology, 2016, 67, 379-389.	2.8	74
59	Flash Pulmonary Edema. Progress in Cardiovascular Diseases, 2009, 52, 249-259.	3.1	69
60	Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ: British Medical Journal, 2017, 356, j4.	2.3	69
61	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	2.8	67
62	Drug induced hypertension â€“ An unappreciated cause of secondary hypertension. European Journal of Pharmacology, 2015, 763, 15-22.	3.5	64
63	The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point. Journal of the American College of Cardiology, 2009, 53, 468-470.	2.8	63
64	Renal Denervation for Resistant Hypertension?. New England Journal of Medicine, 2014, 370, 1454-1457.	27.0	62
65	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Current Hypertension Reports, 2018, 20, 75.	3.5	62
66	Comparative Tolerability Profile of Hypertensive Crisis Treatments. Drug Safety, 1998, 19, 99-122.	3.2	61
67	Risk Factor Variability and CardiovascularÂOutcome. Journal of the American College of Cardiology, 2019, 73, 2596-2603.	2.8	60
68	Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies. American Journal of Medicine, 2011, 124, 896-899.	1.5	59
69	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. American Journal of Cardiology, 2017, 119, 379-387.	1.6	58
70	Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Nonâ€“ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 809-817.	1.6	56
71	Wilder's principle: pre-treatment value determines post-treatment response. European Heart Journal, 2015, 36, 576-579.	2.2	55
72	Angiotensin II Receptor Blockers. Archives of Internal Medicine, 2000, 160, 1905.	3.8	53

#	Article	IF	Citations
73	When an Increase in Central Systolic Pressure Overrides theÂBenefits ofÂHeartÂRate Lowering. Journal of the American College of Cardiology, 2016, 68, 754-762.	2.8	52
74	Verapamil-sustained releaseâ€“based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy. American Heart Journal, 2008, 156, 241-247.	2.7	48
75	Sodium intake, life expectancy, and all-cause mortality. European Heart Journal, 2021, 42, 2103-2112.	2.2	46
76	Resistant hypertension: what the cardiologist needs to know. European Heart Journal, 2015, 36, 2686-2695.	2.2	40
77	Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?. Progress in Cardiovascular Diseases, 2016, 59, 253-261.	3.1	38
78	Do Thiazide Diuretics Confer Specific Protection Against Strokes?. Archives of Internal Medicine, 2003, 163, 2557.	3.8	35
79	Reninâ€“angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. Journal of Hypertension, 2021, 39, 784-794.	0.5	34
80	Salt and heart disease: a second round of â€œbad scienceâ€?. Lancet, The, 2018, 392, 456-458.	13.7	33
81	COVID-19 and Renin Angiotensin Blockers. Circulation, 2020, 141, 2042-2044.	1.6	33
82	Coronary Revascularization Strategy and Outcomes According to Blood Pressure (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 T 498-503.	1.6	32
83	Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease. Hypertension, 2016, 67, 1205-1210.	2.7	32
84	Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction. Circulation, 2017, 135, 2085-2087.	1.6	32
85	Calcium antagonists in hypertension: from hemodynamics to outcomes. American Journal of Hypertension, 2002, 15, S94-S97.	2.0	31
86	Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal, 2010, 31, 2205-2208.	2.2	31
87	Cardioprotection with betaâ€blockers: myths, facts and Pascalâ€™s wager. Journal of Internal Medicine, 2009, 266, 232-241.	6.0	30
88	Blood pressure control in stroke patients. Neurology, 2002, 59, 23-25.	1.1	29
89	Angiotensin receptor blockers: baseline therapy in hypertension?. European Heart Journal, 2009, 30, 2427-2430.	2.2	28
90	Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. European Heart Journal, 2014, 35, 1732-1742.	2.2	28

#	Article	IF	Citations
91	Erythrocyte Membrane Properties in Patients with Essential Hypertension. Cell Biochemistry and Biophysics, 2013, 67, 1089-1102.	1.8	27
92	Efficacy and Safety of Calcium Channel Blocker/Diuretics Combination Therapy in Hypertensive Patients: A Metaâ€Analysis. Journal of Clinical Hypertension, 2015, 17, 193-199.	2.0	27
93	Atherosclerotic Renal Artery Stenosis and Hypertension: Pragmatism, Pitfalls, and Perspectives. American Journal of Medicine, 2016, 129, 635.e5-635.e14.	1.5	27
94	Evolution of calcium antagonists: Past, present, and future. Clinical Cardiology, 2003, 26, 12-16.	1.8	24
95	Individualization of Antihypertensive Therapy: An Approach Based on Hemodynamics and Age. Journal of Clinical Pharmacology, 1981, 21, 517-528.	2.0	23
96	Changing definition of hypertension in guidelines: how innocent a number game?. European Heart Journal, 2018, 39, 2241-2242.	2.2	23
97	Misconceptions and Facts About Beta-Blockers. American Journal of Medicine, 2019, 132, 816-819.	1.5	23
98	Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia. Journal of Hypertension, 2019, 37, 1012-1017.	0.5	22
99	Antihypertensive Efficacy of Aliskiren. Circulation, 2009, 119, 371-373.	1.6	21
100	Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis. Progress in Cardiovascular Diseases, 2020, 63, 527-528.	3.1	21
101	The Blood Pressure Landscape. Journal of the American College of Cardiology, 2018, 72, 1313-1316.	2.8	20
102	Cardiovascular Pathophysiology of Essential Hypertension. Drugs, 1985, 30, 25-34.	10.9	19
103	Trials on the Effect of Cardiac Resynchronization on Arterial Blood Pressure in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 561-568.	1.6	19
104	Arterial Compliance in Systolic Hypertension. Clinical and Experimental Hypertension, 1982, 4, 1037-1044.	0.3	18
105	Beta-Blockers as First-Line Antihypertensive Therapy. Journal of the American College of Cardiology, 2009, 54, 1162-1164.	2.8	18
106	Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Failure Reviews, 2013, 18, 429-437.	3.9	18
107	The J-Point Phenomenon in Aggressive Therapy of Hypertension: New Insights. Current Atherosclerosis Reports, 2012, 14, 124-129.	4.8	17
108	Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. European Heart Journal, 2013, 34, 1095-1098.	2.2	16

#	Article	IF	Citations
109	Age, Blood Pressure Targets, and Guidelines. Circulation, 2018, 138, 128-130.	1.6	16
110	Framingham at 50. Lancet, The, 1998, 352, 1006.	13.7	15
111	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 377, 94-96.	27.0	15
112	Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?. European Heart Journal, 2019, 40, 1787-1789.	2.2	15
113	The LIFE study: the straw that should break the camel's back. European Heart Journal, 2003, 24, 487-489.	2.2	14
114	Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2017, 130, 1325.e1-1325.e12.	1.5	14
115	Blood pressure, cognitive dysfunction, and dementia. Journal of the American Society of Hypertension, 2007, 1, 135-144.	2.3	13
116	Î²-blockers as fourth-line therapy for hypertension: stay the course. International Journal of Clinical Practice, 2008, 62, 1643-1646.	1.7	13
117	Efficacy and Safety of Dual Calcium Channel Blockade for the Treatment of Hypertension: A Meta-Analysis. American Journal of Hypertension, 2013, 26, 287-297.	2.0	13
118	Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle?. American Journal of Medicine, 2016, 129, 769-770.	1.5	13
119	Observations on the blood pressure paradox in heart failure. European Journal of Heart Failure, 2017, 19, 843-845.	7.1	13
120	.â€‰.â€‰. And losartan was no better than placebo. Journal of Human Hypertension, 1999, 13, 649-650.	2.2	12
121	Treatment-resistant hypertension: another Cinderella story. European Heart Journal, 2013, 34, 1175-1177.	2.2	12
122	Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. European Heart Journal, 2014, 35, 1801-1808.	2.2	12
123	Hypertension control and cardiovascular disease. Lancet, The, 2017, 389, 153.	13.7	12
124	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.5	12
125	Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients â‰¥65ÂYears of Age. American Journal of Cardiology, 2016, 118, 1427-1436.	1.6	11
126	Non-invasive pulmonary artery pressure estimation by electrical impedance tomography in a controlled hypoxemia study in healthy subjects. Scientific Reports, 2020, 10, 21462.	3.3	11

#	Article	IF	Citations
127	Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects. Journal of Hypertension, 2021, 39, 1254-1260.	0.5	11
128	Antihypertensive Therapy: Beta-Blockers and Diureticsâ€"Why Do Physicians Not Always Follow Guidelines?. Baylor University Medical Center Proceedings, 2000, 13, 128-134.	0.5	10
129	Serum Uric Acid in Primary Hypertension. Hypertension, 2016, 67, 845-847.	2.7	10
130	The oldest old: does hypertension become essential again?. European Heart Journal, 2018, 39, 3144-3146.	2.2	10
131	Blood Pressure Variability and Arterial Stiffnessâ€"Chicken or Egg?. JAMA Cardiology, 2019, 4, 1050.	6.1	10
132	Stable coronary artery disease. Journal of Hypertension, 2019, 37, 1112-1118.	0.5	10
133	Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention) Tj ETQq1 1 0.784314 rgBT /Overloc 1133-1134.	1.6	9
134	Competing Cardiovascular and Noncardiovascular Risks and Longevity in the Systolic Hypertension in the Elderly Program. American Journal of Cardiology, 2014, 113, 676-681.	1.6	9
135	Hypothyroidism and hypertension: fact or myth?. Lancet, The, 2018, 391, 29-30.	13.7	9
136	GaisbÃ¶ck syndrome (polycythemia and hypertension) revisited. Journal of Hypertension, 2018, 36, 2420-2424.	0.5	9
137	Peripheral edema and headache associated with amlodipine treatment. Journal of Hypertension, 2019, 37, 2093-2103.	0.5	9
138	The muddy waters of the J-curve and coronary revascularization. European Heart Journal, 2020, 41, 1684-1686.	2.2	9
139	On cerebrotoxicity of antihypertensive therapy and risk factor cosmetics. European Heart Journal, 2021, 42, 758-760.	2.2	9
140	Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?. Circulation, 2022, 145, 413-415.	1.6	9
141	Antihypertensive Therapy Is it Different in the Elderly?. Drugs, 1990, 39, 49-54.	10.9	8
142	When Guidelines Need Guidanceâ€¦. American Journal of Medicine, 2008, 121, 742-743.	1.5	8
143	Letter by Messerli et al Regarding Article, â€œThe Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressureâ€. Circulation, 2017, 135, e45-e46.	1.6	8
144	Lowering the Thresholds of Diseases. Journal of the American College of Cardiology, 2018, 71, 119-121.	2.8	8

#	Article	IF	Citations
145	Optimal BP Targets to Prevent Stroke and MI. Journal of the American College of Cardiology, 2021, 78, 1679-1681.	2.8	8
146	Misconceptions and Facts About Treating Hypertension. American Journal of Medicine, 2015, 128, 450-455.	1.5	7
147	Introduction: Controversies in Hypertension. Progress in Cardiovascular Diseases, 2016, 59, 207-208.	3.1	7
148	Diuretic-based regimens for obese patients?. Lancet, The, 2013, 381, 512-513.	13.7	6
149	Salt, Tomato Soup, and the Hypocrisy of the American Heart Association. American Journal of Medicine, 2017, 130, 392-393.	1.5	5
150	Reply. Journal of the American College of Cardiology, 2017, 70, 510.	2.8	5
151	Reply. Journal of the American College of Cardiology, 2017, 70, 120.	2.8	5
152	Of headwind and tailwind, regression to the mean and Wilder's principle. Journal of Hypertension, 2019, 37, 4-5.	0.5	5
153	The alcohol blood pressure paradox. European Heart Journal, 2019, 40, 711-712.	2.2	5
154	When premature is not prematureâ€"the ASCOT studyThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1822-1823.	2.2	4
155	Antihypertensive properties of a highâ€dose combination of trandolapril and verapamilâ€SR. Blood Pressure, 2007, 16, 6-9.	1.5	4
156	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. PLoS ONE, 2015, 10, e0122726.	2.5	4
157	Adverse effects and tolerability of Î² blockers. BMJ, The, 2016, 353, i3142.	6.0	4
158	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	2.7	4
159	What Ever Happened to Cardioprotection With Î²-Blockers?. Mayo Clinic Proceedings, 2018, 93, 401-403.	3.0	4
160	Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?. Global Heart, 2022, 17, 17.	2.3	4
161	Blood Pressure and Stroke. Journal of the American College of Cardiology, 2011, 57, 114-115.	2.8	3
162	Left-ventricular hypertrophy in obesity. Journal of Hypertension, 2014, 32, 1542-1543.	0.5	3

#	Article	IF	Citations
163	Misconceptions and Facts About Mitral Regurgitation. American Journal of Medicine, 2016, 129, 919-923.	1.5	3
164	Are ACE inhibitors acceptable ingredients in polypills?. Lancet, The, 2017, 390, 26.	13.7	3
165	Ephemeral Coronary Heart Disease. European Heart Journal, 2019, 40, 1906-1908.	2.2	3
166	Implications of Guideline Updates for the Management of Apparent Treatment Resistant Hypertension in the United States (A NCDR Research to Practice [R2P] Project). American Journal of Cardiology, 2020, 125, 63-67.	1.6	3
167	Renal Denervation. JACC: Cardiovascular Interventions, 2020, 13, 2934-2936.	2.9	3
168	Soluble fmsâ€like tyrosine kinase 1 (sFltâ€1): A novel biochemical marker for acute fatty liver of pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1876-1884.	2.8	3
169	Efficacy of folic acid in primary prevention of stroke among patients with hypertension in China. Journal of the American Society of Hypertension, 2015, 9, 665-667.	2.3	2
170	Heart rate lowering by beta-blockade and cardiovascular events. Journal of Hypertension, 2016, 34, 2102-2103.	0.5	2
171	Ivabradine in Coronary Heart Diseaseâ€"The Emperor Has No Clothes. American Journal of Cardiology, 2017, 120, e15.	1.6	2
172	Hypothyroidism as a cause of secondary hypertension - Myth dispelled. Journal of the American Society of Hypertension, 2017, 11, 615.	2.3	2
173	Systolic Hypertension, Preeclampsia-Related Mortality, and Stroke In California. Obstetrics and Gynecology, 2019, 134, 880-880.	2.4	2
174	Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension. JAMA Internal Medicine, 2020, 180, 1133.	5.1	2
175	Alcohol and atrial fibrillation: not all drinks are created equal. European Heart Journal, 2021, 42, 2506-2506.	2.2	2
176	Importance of pulse pressure at low systolic blood pressure. European Heart Journal, 2022, 43, 540-540.	2.2	2
177	Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials. European Journal of Preventive Cardiology, 2022, 29, e319-e322.	1.8	2
178	Suttonâ€™s law and dietary Na+/K+ intake in cardiovascular disease. European Heart Journal, 2022, 43, 2876-2877.	2.2	2
179	Î²-Blockers: No longer an option for uncomplicated hypertension. Current Cardiovascular Risk Reports, 2008, 2, 280-285.	2.0	1
180	Simpleâ€Minded Antihypertensive Treatment: Of Assumptions, Potpourri, and Sausages. Journal of Clinical Hypertension, 2009, 11, 702-706.	2.0	1

#	Article	IF	Citations
181	Fraudulent data: an apology and the fate of angiotensin receptor blockers. BMJ, The, 2013, 347, f5549-f5549.	6.0	1
182	Feto-maternal interactions. Current Opinion in Cardiology, 2015, 30, 391-392.	1.8	1
183	Reply. Journal of the American College of Cardiology, 2016, 68, 430-431.	2.8	1
184	In Replyâ€"The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality. Mayo Clinic Proceedings, 2016, 91, 972-975.	3.0	1
185	Salt and Blood Pressure: Cutting Through the Scientific Fog. Current Hypertension Reports, 2017, 19, 47.	3.5	1
186	Heart Failure WithÂPreserved EjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2458.	2.8	1
187	Renal denervation: will the Phoenix rise from the ashes?. European Heart Journal, 2017, 38, 3321-3323.	2.2	1
188	In polypills, as in any recipe, it's ingredients that matter. Journal of Hypertension, 2017, 35, 2550.	0.5	1
189	Alter ego(s) in coronary artery disease. European Heart Journal, 2018, 39, 3987-3998.	2.2	1
190	Beta Blockers and Calcium Channel Blockers. Contemporary Cardiology, 2019, , 73-88.	0.1	1
191	Letter by Messerli et al Regarding Article â€œEarly Life Factors and Longitudinal Blood Pressure Trajectories Are Associated With Elevated Blood Pressure in Early Adulthood: BT20 Cohortâ€• Hypertension, 2019, 73, e83.	2.7	1
192	Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics. International Journal of Cardiology: Hypertension, 2020, 7, 100054.	2.2	1
193	Letter by Messerli et al Regarding Article, â€œIncidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohortâ€• Circulation, 2020, 142, e27-e28.	1.6	1
194	MANAGEMENT OF CLOT IN TRANSIT IN A POST-PARTUM COVID-19 PATIENT. Journal of the American College of Cardiology, 2021, 77, 2920.	2.8	1
195	Salt consumption at a population level remains remarkably steady over time. European Heart Journal, 2021, 42, 2134-2134.	2.2	1
196	Ivabradine in POTS. Journal of the American College of Cardiology, 2021, 77, 3141-3142.	2.8	1
197	Lowering systolic blood pressure to 120â€‰mmHg or The Lancetâ€™s true grit. European Heart Journal, 2021, 42, 2052-2059.	2.2	1
198	Cerebrotoxicity of antihypertensive therapy in the UK Biobank Cohort Study. European Heart Journal, 2021, 42, 4282.	2.2	1

#	Article	IF	Citations
199	Quo usque tandem abutere, Catilina, patientia nostra?. Swiss Medical Weekly, 2016, 146, w14344.	1.6	1
200	Introduction: Antihypertensive therapy: Past, present, and future. Cardiovascular Drugs and Therapy, 1994, 8, 7-9.	2.6	0
201	The crumbling of dual renin-angiotensin system blockade. Current Hypertension Reports, 2009, 11, 159-161.	3.5	0
202	Cardiovascular Death and Cancer Deathâ€"Competing Risk?. American Journal of Cardiology, 2012, 109, 1687.	1.6	0
203	Is Dual Renin-Angiotensin-System Blockade Associated With Increased Risk of Stroke?. JACC: Heart Failure, 2013, 1, 454-457.	4.1	0
204	Letter by Argulian and Messerli Regarding Article, â€œEffect of Early Metoprolol on Infarct Size in ST-Segmentâ€“Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trialâ€• Circulation, 2014, 130, e18.	1.6	0
205	The Reply. American Journal of Medicine, 2014, 127, e19.	1.5	0
206	Futility of Imaging Atherosclerotic Renal Artery Stenosis?. American Journal of Medicine, 2015, 128, e25.	1.5	0
207	Optimal blood pressure targets in 2014 â€“ Does the guideline recommendation match the evidence base?. Hipertension Y Riesgo Vascular, 2015, 32, 71-82.	0.6	0
208	Cognitive Decline, Blood Pressure Control and Variability: A Relentless Downward Spiral?. Journal of the American Medical Directors Association, 2016, 17, 1160-1161.	2.5	0
209	Safety vs Efficacy of Lowering Blood Pressure. JAMA Cardiology, 2017, 2, 1398.	6.1	0
210	The Reply. American Journal of Medicine, 2017, 130, e321.	1.5	0
211	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.5	0
212	Reply. JACC: Heart Failure, 2017, 5, 851.	4.1	0
213	The Reply. American Journal of Medicine, 2018, 131, e27.	1.5	0
214	Reply. JACC: Heart Failure, 2018, 6, 890.	4.1	0
215	In Hypertension as Elsewhere in Medicine, One Size Does Not Fit All. Hypertension, 2018, 72, 829-831.	2.7	0
216	When Guideline Authors Ignore Their Own Guidelines. Hypertension, 2018, 72, e19.	2.7	0

#	Article	IF	Citations
217	Age, Cardiovascular Risk, and Blood Pressure Target. Journal of the American College of Cardiology, 2018, 72, 818-819.	2.8	0
218	Reninâ€“Angiotensinâ€“Aldosterone Axis Modulators and Other Vasodilators. Contemporary Cardiology, 2019, , 61-72.	0.1	0
219	Postholiday Heart Failure Triggered by Dietary Salt Excess. JAMA Internal Medicine, 2019, 179, 1006.	5.1	0
220	Letter by Messerli and Bangalore Regarding Article, â€œAssociation of Blood Pressure Measurements With Peripheral Artery Disease Eventsâ€• Circulation, 2019, 139, 1854-1854.	1.6	0
221	Social media and predictive analysis regarding dietary approaches to stop hypertension. Progress in Cardiovascular Diseases, 2021, 68, 88-90.	3.1	0
222	Reply. Journal of Hypertension, 2021, 39, 1726-1727.	0.5	0
223	The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo. Annals of Translational Medicine, 2016, 4, 321-321.	1.7	0
224	How much salt is too much salt?. Anatolian Journal of Cardiology, 2019, 22, 2-4.	0.9	0
225	Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?. Cleveland Clinic Journal of Medicine, 2020, 87, 9.1-9.	1.3	0
226	Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR. Blood Pressure Supplement, 2007, 1, 6-9.	0.2	0
227	Safety and Efficacy of Thiazide Diuretics in Hypertension. American Journal of Medicine, 2022, 135, e109.	1.5	0